Stocktoria
Cardiff Oncology, Inc. CRDF
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2004-07-27
Cardiff Oncology, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $593,000 | $683,000 | $488,000 | $386,000 | $359,000 |
| R&D expense | — | — | — | $27.1M | $17.4M |
| SG&A expense | $14.2M | $12.5M | $13.0M | $13.2M | $11.8M |
| Operating income | -$49.0M | -$48.7M | -$45.4M | -$39.9M | -$28.9M |
| Interest expense | — | — | — | — | $0 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$45.9M | -$45.4M | -$41.4M | -$38.7M | -$28.3M |
| EPS (diluted) | $-0.69 | $-0.95 | $-0.93 | $-0.89 | $-0.73 |
| Operating cash flow | -$37.9M | -$37.7M | -$30.9M | -$33.8M | -$23.0M |
| Free cash flow | -$38.0M | -$37.8M | -$31.5M | -$34.8M | -$23.2M |
| Cash & equivalents | $17.5M | $51.5M | $21.7M | $16.3M | $11.9M |
| Total assets | $61.9M | $97.2M | $81.6M | $116.2M | $149.5M |
| Total liabilities | $16.5M | $14.2M | $11.9M | $9.8M | $9.1M |
| Shareholders' equity | $45.4M | $82.9M | $69.7M | $106.3M | $140.4M |
Source: SEC EDGAR filings · CIK 0001213037 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.